This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Oligometastases
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Rationale: SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer. High efficacy in terms of local control of metastatic lesions treated has been shown. Nevertheless, the precise effect of SABR upon progression-free- and overall survival in these patients is unknown. To further evaluate and develop local treatment options in metastatic disease, more information is necessary regarding the impact upon - and the pattern of - disease progression of local treatment options such as SABR. Objective: To determine the effect upon progression free survival and upon tumorload relative to baseline, both at one year after randomisation of immediate SABR versus delayed SABR (a scan-and-personalise policy). Secondarily, patterns of progression, patient-reported symptoms and quality of life will be monitored.

Provided treatments

  • Radiation: Stereotactic Ablative Radiotherapy (SABR)
Tris trial is registered with FDA with number: NCT02414334. The sponsor of the trial is University Medical Center Groningen and it is looking for 40 volunteers for the current phase.
Official trial title:
Immediate Versus Delayed Stereotactic Ablative Radiotherapy (SABR) for Patients With Pulmonary Oligometastases From Colorectal Cancer: SABR SCAN Trial A Randomised Clinical Trial